Skip to main content

Table 3 The association between high- and low- immune risk score and OS of LUAD patients in training, validation dataset-1 and validation dataset-2

From: An individualized immune prognostic signature in lung adenocarcinoma

  Training dataset (N = 520) Validation dataset-1 (N = 436) Validation dataset-2 (N = 381)
(High/low) HR (95% CI) p value (High/low) HR (95% CI) p value (High/low) HR (95% CI) p value
Total 215/305 2.77 (2.08–3.67) < 0.01 183/253 1.56 (1.20–2.02) < 0.01 109/272 1.83 (1.24–2.78) < 0.01
Age
 < 70 165/236 2.97 (2.09–4.24) < 0.01 119/171 1.53 (1.11–2.13) 0.01 56/119 1.93 (1.06–3.52) 0.03
 ≥ 70 50/69 2.87 (1.76–4.69) < 0.01 64/82 1.71 (1.12–2.63) 0.05 53/153 1.82 (1.08–3.05) 0.02
Gender
 Male 132/139 2.28 (1.57–3.31) < 0.01 102/116 1.42 (1.01–2.00) 0.04 54/114 1.95 (1.14–3.33) < 0.01
 Female 83/166 3.47 (2.23–5.39) < 0.01 81/176 1.66 (1.11–2.47) 0.01 55/158 1.66 (0.93–2.95) 0.09
Stage
 I/II 205/297 2.73 (2.03–3.65) < 0.01 150/218 1.66 (1.23–2.25) < 0.01 85/226 2.06 (1.29–3.29) < 0.01
 III/IV 10/8 2.71 (0.83–8.87) 0.10 35/33 0.95 (0.57–1.59) 0.85 24/46 1.20 (0.59–2.47) 0.61
Purity
 < 0.5 146/174 3.33 (2.30–4.82) < 0.01 52/61 1.95 (1.11–3.41) 0.02 42/84 1.70 (0.89–3.24) 0.11
 ≥ 0.5 69/131 2.11 (1.33–3.33) 0.01 131/192 1.50 (1.11–2.02) < 0.01 67/188 1.93 (1.17–3.13) < 0.01
  1. CI confidence interval, HR hazard ratio, LUAD lung adenocarcinoma, OS overall survival